Nimotuzumab (h-R3, BIOMAb EGFR, Biocon, India; TheraCIM, CIMYM Biosciences, Canada; Theraloc, Oncoscience, Europe, CIMAher, Center of Molecular Immunology...
8 KB (811 words) - 23:38, 22 May 2024
India include INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor (Everolimus)...
30 KB (2,613 words) - 18:01, 2 July 2024
YM Biosciences (section Nimotuzumab research)
The company also advanced other clinical-stage products, including Nimotuzumab, an EGFR-targeting monoclonal antibody, and CYT997, a vascular disrupting...
5 KB (515 words) - 02:23, 24 January 2021
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
121 KB (13,799 words) - 06:42, 1 July 2024
HER2/neu overexpression targets the HER2/neu (erbB2) receptor humanized nimotuzumab approved in squamous cell carcinomas, Glioma clinical trials for other...
47 KB (4,802 words) - 02:10, 28 June 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
150 KB (15,741 words) - 10:52, 27 June 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
31 KB (3,413 words) - 23:30, 21 June 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
68 KB (5,993 words) - 00:47, 13 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
13 KB (1,177 words) - 18:50, 10 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
42 KB (3,935 words) - 04:01, 30 April 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
92 KB (8,667 words) - 19:29, 28 June 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
25 KB (2,085 words) - 03:15, 6 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
10 KB (579 words) - 06:46, 26 June 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
16 KB (1,784 words) - 04:08, 6 January 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
5 KB (412 words) - 23:17, 19 June 2023
nimetazepam (INN) nimidane (INN) nimodipine (INN) nimorazole (INN) Nimotop nimotuzumab (INN) nimustine (INN) niometacin (INN) Nipent Nipent (Parke-Davis Pharmaceutical...
9 KB (421 words) - 04:33, 2 July 2024
(Russia) plaque psoriasis, psoriatic arthritis, ankylosing spondylitis Nimotuzumab BioMab-EGFR, Theracim, Theraloc mab humanized epidermal growth factor...
135 KB (4,054 words) - 22:35, 2 July 2024
of molecular immunology (CIM) developed nimotuzumab, a monoclonal antibody used to treat cancer. Nimotuzumab is an inhibitor of epidermal growth factor...
78 KB (9,229 words) - 01:11, 12 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
11 KB (934 words) - 06:00, 10 April 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
20 KB (1,543 words) - 06:38, 10 March 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
22 KB (1,993 words) - 23:37, 23 March 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
17 KB (1,489 words) - 05:47, 7 April 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
110 KB (10,711 words) - 05:46, 12 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
34 KB (3,021 words) - 04:42, 11 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
27 KB (3,071 words) - 04:54, 3 June 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
45 KB (5,341 words) - 08:28, 10 June 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
108 KB (12,653 words) - 16:16, 10 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
24 KB (2,877 words) - 10:08, 2 June 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
63 KB (7,427 words) - 14:51, 9 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
10 KB (661 words) - 04:10, 26 June 2024